secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-05-29T20:35:27+00:00
Accession:  0001730430-26-000029
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting
--------------------------------------------------------------------------------

- Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.
- PricewaterhouseCoopers LLP approved as both UK statutory auditor and US independent auditor with overwhelming votes.
- Advisory vote on named executive officer compensation passed with 48.1M for and 1.3M against.
- All eight proposals, including director elections, auditor appointments, and remuneration reports, were duly passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/0001730430-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/knsa-20260529x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer